DRUG LEVELS OF LOPINAVIR/RITONAVIR IN MEN AND WOMEN

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 A5223是对78例HIV-1感染受试者进行的一项非随机前瞻性评价，旨在确定LPV在男性和女性中的药代动力学（PK）。 受试者将按性别、人种和种族分层。 他们将接受洛匹那韦/利托那韦（LPV/RTV）早晨给药前和给药后12小时内采集的血浆样本的药代动力学评价。 这项研究将使我们开始更好地了解抗逆转录病毒药物在妇女中的安全性和有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5223 is a non-randomized prospective evaluation of78 HIV-1- infected subjects designed to determine the pharmacokinetics (PK) of LPV in men and women. Subjects will be stratified by sex, race and ethnicity. They will undergo pharmacokinetic evaluations on plasma samples obtained prior to and up to 12 hours after the administration of the morning dose of lopinavir/ritonavir (LPV/RTV). This study will allow us to begin to have a better understanding of the safety and efficacy of antiretroviral agents among women.